RCS - Diaceutics PLC - Canaccord Genuity 43rd Annual Growth Conference

DiaceuticsAnnouncement

04/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230804:nRSD2666Ia&default-theme=true

RNS Number : 2666I  Diaceutics PLC  04 August 2023

04 August 2023

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

Diaceutics to present at Canaccord Genuity 43rd Annual Growth Conference in
Boston

 

Diaceutics PLC (https://www.diaceutics.com/)  (AIM: DXRX), a leading
technology and solutions provider to the pharmaceutical industry, today
announces that management will attend and present at the Canaccord Genuity
43(rd) Annual Growth Conference taking place on August 7-10 in Boston, MA.

 

The Conference brings together investors from around the world with some of
the best and most promising growth companies in Canaccord's core sectors -
Technology, Healthcare, Digital & Tech-Enabled Health, Sustainability,
Industrials, and Consumer & Retail. For more information please click
here
(https://www.canaccordgenuity.com/capital-markets/events-and-conferences/43rd-annual-growth-conference/)
.

 

Enquiries:

 Diaceutics PLC                                        Tel: +44 (0)28 9040 6500
 Peter Keeling, Chief Executive Officer               investorrelations@diaceutics.com

 Ryan Keeling, Chief Innovation Officer

 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland

 Kate Hanshaw

 Alma PR                                              Tel: +44 (0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the commercialisation
of their precision medicines, enabled by our proprietary DXRX platform.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKNBQQBKDFFK